{"BackgroundSemaglutide,": [0], "a": [1, 39, 62, 92, 101, 114, 128, 135, 263, 288], "glucagon-like": [2], "peptide-1": [3], "receptor": [4], "agonist,": [5], "has": [6], "been": [7], "shown": [8], "to": [9, 95, 150, 155, 164, 216, 222, 270], "reduce": [10, 24], "the": [11, 33, 71, 74, 138, 172, 189, 194, 201, 206, 226, 235, 243, 274], "risk": [12, 26], "of": [13, 35, 52, 73, 78, 85, 103, 116, 137, 142, 162, 175, 188, 200, 225, 265, 276, 291], "adverse": [14], "cardiovascular": [15, 25, 59, 110, 119, 182, 250, 279], "events": [16, 220], "in": [17, 32, 67, 76, 91, 127, 186, 193, 198, 205, 230, 234, 242, 272, 308], "patients": [18, 49, 144, 191, 203, 232, 240, 247], "with": [19, 28, 248], "diabetes.": [20, 86], "Whether": [21], "semaglutide": [22, 99, 152, 165, 195, 236, 261], "can": [23], "associated": [27], "overweight": [29, 253], "and": [30, 61, 153, 171, 197, 238, 252, 305], "obesity": [31, 255], "absence": [34], "diabetes": [36], "is": [37], "unknown.MethodsIn": [38], "multicenter,": [40], "double-blind,": [41], "randomized,": [42], "placebo-controlled,": [43], "event-driven": [44], "superiority": [45], "trial,": [46], "we": [47], "enrolled": [48], "45": [50], "years": [51], "age": [53], "or": [54, 80, 106, 124, 166, 254, 284], "older": [55], "who": [56], "had": [57], "preexisting": [58, 249], "disease": [60, 251], "body-mass": [63], "index": [64], "(the": [65], "weight": [66], "kilograms": [68], "divided": [69], "by": [70, 295], "square": [72], "height": [75], "meters)": [77], "27": [79], "greater": [81], "but": [82, 256], "no": [83], "history": [84], "Patients": [87], "were": [88, 145, 148], "randomly": [89], "assigned": [90, 149], "1:1": [93], "ratio": [94], "receive": [96, 151, 156], "once-weekly": [97], "subcutaneous": [98, 260], "at": [100, 262, 287], "dose": [102, 264], "2.4": [104, 266], "mg": [105, 267], "placebo.": [107, 157], "The": [108, 158], "primary": [109, 181], "end": [111], "point": [112], "was": [113, 132, 168, 177, 268], "composite": [115], "death": [117, 277], "from": [118, 278], "causes,": [120, 280], "nonfatal": [121, 125, 281, 285], "myocardial": [122, 282], "infarction,": [123, 283], "stroke": [126, 286], "time-to-first-event": [129], "analysis.": [130], "Safety": [131], "also": [133], "assessed.Download": [134], "PDF": [136], "Research": [139], "Summary.ResultsA": [140], "total": [141], "17,604": [143], "enrolled;": [146], "8803": [147, 190], "8801": [154, 202], "mean": [159, 173, 289], "(\u00b1SD)": [160], "duration": [161, 174], "exposure": [163], "placebo": [167, 207, 244, 271], "34.2\u00b113.7": [169], "months,": [170], "follow-up": [176, 290], "39.8\u00b19.4": [178], "months.": [179, 293], "A": [180], "end-point": [183], "event": [184], "occurred": [185, 229], "569": [187], "(6.5%)": [192], "group": [196, 208, 237, 245], "701": [199], "(8.0%)": [204], "(hazard": [209], "ratio,": [210], "0.80;": [211], "95%": [212], "confidence": [213], "interval,": [214], "0.72": [215], "0.90;": [217], "P<0.001).": [218], "Adverse": [219], "leading": [221], "permanent": [223], "discontinuation": [224], "trial": [227], "product": [228], "1461": [231], "(16.6%)": [233], "718": [239], "(8.2%)": [241], "(P<0.001).ConclusionsIn": [246], "without": [257], "diabetes,": [258], "weekly": [259], "superior": [269], "reducing": [273], "incidence": [275], "39.8": [292], "(Funded": [294], "Novo": [296], "Nordisk;": [297], "SELECT": [298], "ClinicalTrials.gov": [299], "number,": [300], "NCT03574597.)": [301], "Quick": [302], "Take": [303], "Semaglutide": [304], "Cardiovascular": [306], "Outcomes": [307], "Obesity": [309], "2m": [310], "17s": [311]}